- Home
- NU vs REGN Comparison
NU vs REGN Comparison
Compare NU & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NU
- REGN
- Stock Information
- Founded
- NU 2013
- REGN 1988
- Country
- NU Brazil
- REGN United States
- Employees
- NU N/A
- REGN N/A
- Industry
- NU Finance: Consumer Services
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- NU Finance
- REGN Health Care
- Exchange
- NU Nasdaq
- REGN Nasdaq
- Market Cap
- NU 57.9B
- REGN 63.4B
- IPO Year
- NU 2021
- REGN 1991
- Fundamental
- Price
- NU $13.58
- REGN $547.31
- Analyst Decision
- NU Buy
- REGN Buy
- Analyst Count
- NU 8
- REGN 22
- Target Price
- NU $15.50
- REGN $839.91
- AVG Volume (30 Days)
- NU 75.6M
- REGN 1.2M
- Earning Date
- NU 08-14-2025
- REGN 08-01-2025
- Dividend Yield
- NU N/A
- REGN 0.64%
- EPS Growth
- NU 69.16
- REGN 16.49
- EPS
- NU 0.44
- REGN 39.43
- Revenue
- NU $5,645,577,000.00
- REGN $14,085,700,000.00
- Revenue This Year
- NU $166.94
- REGN N/A
- Revenue Next Year
- NU $26.23
- REGN $6.78
- P/E Ratio
- NU $30.92
- REGN $13.88
- Revenue Growth
- NU 32.91
- REGN 7.52
- 52 Week Low
- NU $9.01
- REGN $476.49
- 52 Week High
- NU $16.15
- REGN $1,211.20
- Technical
- Relative Strength Index (RSI)
- NU 63.18
- REGN 57.41
- Support Level
- NU $13.34
- REGN $514.79
- Resistance Level
- NU $13.99
- REGN $531.21
- Average True Range (ATR)
- NU 0.47
- REGN 13.62
- MACD
- NU 0.12
- REGN 6.38
- Stochastic Oscillator
- NU 83.76
- REGN 96.86
About NU Nu Holdings Ltd.
Nu Holdings Ltd provides digital banking services. It offers several financial services such as Credit cards, Personal accounts, Investments, Personal Loans, Insurance, Mobile payments, Business Accounts, and Rewards. The company earns the majority of its revenue in Brazil.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).